Key result
Despite evidence-based guidelines for lifestyle and pharmacologic interventions, high coronary risk in women continues to be underrecognized and undertreated.
Despite evidence-based guidelines, women remain underrecognized for high coronary risk and undertreated with preventive therapies like statins.
Demands heightened clinical vigilance for coronary risk in women; leaves open effective strategies to close persistent treatment gaps.
Coronary heart disease (CHD) continues to be the leading cause of death among women in the United States. Evidence-based guidelines of the American Heart Association (AHA) offer clinicians recommendations for preventing CHD in women delineating particular lifestyle, risk factor, and pharmacologic interventions. Cigarette smoking, physical inactivity, inappropriate diet, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome contribute to the risk of CHD in women, as in men. Lifestyle interventions substantially reduce that risk. Many women, however, require pharmacotherapy to control hypertension, dyslipidemia, and diabetes to levels required for decreasing risk. New findings from clinical trials featuring women may enhance their CHD risk prediction and treatment. However, high coronary risk in many women continues to be underrecognized, and women remain undertreated with statins and other therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Nanette K. Wenger (2007) conducted a review in Coronary heart disease. Despite evidence-based guidelines for lifestyle and pharmacologic interventions, high coronary risk in women continues to be underrecognized and undertreated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: